Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer: Clinical Outcomes and Toxicity

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Uterine Neoplasms (Version 1.2020). [accessed 2020 Mar 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine_blocks.pdf
   Google Scholar
• Hamed RH, Abdelkhalek SE. Clinical outcome of docetaxel in advanced or metastatic endometrial cancer. Hematol Oncol Stem Cell Ther. 2012;5(3):146–151. doi:10.5144/1658-3876.2012.146.
   PubMedGoogle Scholar
• Kraemer O, Rapiti E, Huber D, et al. Stage IVB uterine cancer: clinical course and survival of patients with single and multiple metastases. Eur J Gynaecol. Oncol. 2015;36:529–532.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB uterine carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000;78(2):85–91. doi:10.1006/gyno.2000.5843.
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi:10.1200/JCO.1995.13.1.8.
   PubMed Web of Science ®Google Scholar
• Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist. 2012;17(8):1100–1107. doi:10.1634/theoncologist.2012-0092.
   PubMed Web of Science ®Google Scholar
• Kavanagh BD, McGarry RC, Timmerman RD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin Radiat Oncol. 2006;16(2):77–84. doi:10.1016/j.semradonc.2005.12.003.
   PubMed Web of Science ®Google Scholar
• Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128–1137. doi:10.1002/cncr.29161.
   PubMed Web of Science ®Google Scholar
• Mills MN, Reddy AV, Richardson L, Richardson KM, Kersh CR. The prognostic role of pretreatment neutrophil to lymphocyte ratio (NLR) in malignant adrenal lesions treated with stereotactic body radiation therapy (SBRT). Am J Clin Oncol. 2019;42(12):945–950. doi:10.1097/COC.0000000000000610.
   PubMed Web of Science ®Google Scholar
• Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 2012;110(11 Pt B):E737–E743. doi:10.1111/j.1464-410X.2012.11550.x.
   PubMedGoogle Scholar
• Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–453. doi:10.1200/JCO.2017.75.4853.
   PubMed Web of Science ®Google Scholar
• Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650. doi:10.1001/jamaoncol.2020.0147.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Yu J, Nuerjiang S, Li Z, Wang D, Wang X, et al. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer. Cancer Med. 2019;8(10):4605–4614. doi:10.1002/cam4.2366.
   PubMed Web of Science ®Google Scholar
• Lazzari R, Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, et al. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Radiat Oncol Biol Phys. 2018;101(3):650–660. doi:10.1016/j.ijrobp.2018.03.058.
   PubMed Web of Science ®Google Scholar
• Mesko S, Sandler K, Cohen J, Konecny G, Steinberg M, Kamrava M, et al. Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies. Int J Gynecol Cancer. 2017;27(2):403–408. doi:10.1097/IGC.0000000000000869.
   PubMed Web of Science ®Google Scholar
• Iftode C, Dʼagostino GR, Tozzi A, Comito T, Franzese C, De Rose F, et al. Stereotactic body radiation therapy in oligometastatic ovarian cancer: a promising therapeutic approach. Int J Gynecol Cancer. 2018;28(8):1507–1513. doi:10.1097/IGC.0000000000001324.
   PubMed Web of Science ®Google Scholar
• Macchia G, Lazzari R, Colombo N, Laliscia C, Capelli, G, D'Agostino GR, et al. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Oncologist. 2019; 25(2):e311–e320.
   PubMed Web of Science ®Google Scholar
• Laliscia C, Fabrini MG, Delishaj D, Morganti R, Greco C, Cantarella M, et al. Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer. Int J Gynecol Cancer. 2017;27(2):396–402. doi:10.1097/IGC.0000000000000885.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Brindle J, Waggoner S, Zanotti K, Resnick K, Fusco N, et al. Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies. Front Oncol. 2012;2:181. doi:10.3389/fonc.2012.00181.
   PubMedGoogle Scholar
• Hasan S, Ricco A, Jenkins K, Lanciano R, Hanlon A, Lamond J, et al. Survival and control prognosticators of recurrent gynecological malignancies of the pelvis and para-aortic region treated with stereotactic body radiation therapy. Front Oncol. 2016;6:249.
   PubMed Web of Science ®Google Scholar
• Seo Y, Kim MS, Yoo HJ, Jang WI, Rhu SY, Choi SC, et al. Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: Feasibility and complication. Asia-Pac J Clin Oncol. 2016;12(2):e280–e288. doi:10.1111/ajco.12185.
   PubMed Web of Science ®Google Scholar
• Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6(11):8491–8524. doi:10.18632/oncotarget.3455.
   PubMedGoogle Scholar
• Di Lascio S, Pagani O. Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel). 2014;9(1):7–14. doi:10.1159/000358750.
   PubMed Web of Science ®Google Scholar
• Otake S, Goto T. Stereotactic radiotherapy for oligometastasis. Cancers (Basel). 2019;11(2):133. doi:10.3390/cancers11020133.
   Web of Science ®Google Scholar
• Palacios-Eito A, Béjar-Luque A, Rodríguez-Liñán M, García-Cabezas S. Oligometastases in prostate cancer: ablative treatment. World J Clin Oncol. 2019;10(2):38–51. doi:10.5306/wjco.v10.i2.38.
   PubMed Web of Science ®Google Scholar
• Parker SM, Siochi RA, Wen S, Mattes MD. Impact of tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors. Pract Radiat Oncol. 2019;9(1):e90–e97. doi:10.1016/j.prro.2018.09.003.
   PubMed Web of Science ®Google Scholar
• Ricco A, Davis J, Rate W, Yang J, Perry D, Pablo J, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience. Radiat Oncol. 2017;12(1):35. doi:10.1186/s13014-017-0773-4.
   PubMedGoogle Scholar
• Loi M, Frelinghuysen M, Klass ND, Oomen-De Hoop E, Granton PV, Aerts J, et al. Locoregional control and survival after lymph node SBRT in oligometastatic disease. Clin Exp Metastasis. 2018;35(7):625–633. doi:10.1007/s10585-018-9922-x.
   PubMed Web of Science ®Google Scholar
• Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014;6(4):369–374. doi:10.3978/j.issn.2072-1439.2013.12.03.
   PubMed Web of Science ®Google Scholar
• Scorsetti M, Clerici E, Comito T. Stereotactic body radiation therapy for liver metastases. J Gastrointest Oncol. 2014;5(3):190–197. doi:10.3978/j.issn.2078-6891.2014.039.
   PubMedGoogle Scholar
• Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336–342. doi:10.1016/j.ijrobp.2012.12.021.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhou YK, Chen YX, Zeng ZC. Magnitude and influencing factors of respiration-induced liver motion during abdominal compression in patients with intrahepatic tumors. Radiat Oncol. 2017;12(1):9. doi:10.1186/s13014-016-0762-z.
   PubMedGoogle Scholar
• Lu L, Diaconu C, Djemil T, Videtic GM, Abdel-Wahab M, Yu N, et al. Intra- and inter-fractional liver and lung tumor motions treated with SBRT under active breathing control. J Appl Clin Med Phys. 2018;19(1):39–45. doi:10.1002/acm2.12220.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Brock KK, Kazanjian S, Fitch D, McGinn CJ, Lawrence TS, et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51(5):1410–1421. doi:10.1016/S0360-3016(01)02653-0.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058. doi:10.1016/S0140-6736(18)32487-5.
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019;19(1):816. doi:10.1186/s12885-019-5977-6.
   PubMed Web of Science ®Google Scholar
• Nicosia L, Cuccia F, Mazzola R, et al. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J. Cancer Res. Clin. Oncol. 2020;146(9):2351–2358.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–1682. doi:10.1016/S1470-2045(16)30532-0.
   PubMed Web of Science ®Google Scholar
• Lee YH, Kang KM, Choi HS, Ha IB, Jeong H, Song JH, et al. Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases. Thorac Cancer. 2018;9(12):1671–1679. doi:10.1111/1759-7714.12880.
   PubMed Web of Science ®Google Scholar
• Greco C, Pares O, Pimentel N, Louro V, Morales J, Nunes B, et al. Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy. Int J Radiat Oncol Biol Phys. 2019;104(3):593–603. doi:10.1016/j.ijrobp.2019.02.033.
   PubMed Web of Science ®Google Scholar